Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries

Abraham M. Getaneh a , Xiao Li a,⇑ , Zhuxin Mao a , Caroline K. Johannesen b,c , Elisa Barbieri d , Jojanneke van Summeren e , Xin Wang f,g , Sabine Tong h , Eugenio Baraldi i , Emily Phijffer j , Caterina Rizzo k , Maarten van Wijhe b,l , Terho Heikkinen m, Louis Bontj,n , Lander Willem a , Mark Jit o , Philippe Beutels a , Joke Bilcke a , for Respiratory Syncytial Virus Consortium in Europe (RESCEU) investigators

Respiratory syncytial virus (RSV) imposes a substantial burden on pediatric hospital capacity in Europe. Promising prophylactic interventions against RSV including monoclonal antibodies (mAb) and maternal immunizations (MI) are close to licensure. Therefore, we aimed to evaluate the costeffectiveness of potential mAb and MI interventions against RSV in infants, for six European countries. Methods: We used a static cohort model to compare costs and health effects of four intervention programs to no program and to each other: year-round MI, year-round mAb, seasonal mAb (October to April), and seasonal mAb plus a catch-up program in October. Input parameters were obtained from national registries and literature. Influential input parameters were identified with the expected value of partial perfect information and extensive scenario analyses (including the impact of interventions on wheezing and asthma).

Read paper of the month | February 2023